Updates on the Management of Motor Signs and Symptoms of Parkinson’s Disease

Neurologists, Geriatricians, Primary Care physicians, Internal medicine physicians, Nurse practitioners, Physician assistants

Activity Information

Credits: 0.5 AMA PRA Category 1 Credit(s)
Launch Date: April 07, 2020
Expiration Date: April 07, 2021

COURSE FACULTY

Stuart Isaacson, MD
Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Rajesh Pahwa, MD
Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, Kansas

LEARNING OBJECTIVES

  1. Review the efficacy and safety of agents for the management of early motor symptoms of PD     
  2. Outline pharmacologic options for managing motor fluctuations in PD
  3. Describe factors that should be considered when using an on-demand management plan for late motor symptoms

COURSE INFORMATION

Information on this Educational Activity

Disclosure of Conflicts of Interest
University of Cincinnati requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the University’s policy. University of Cincinnati is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The University of Cincinnati and Clinical Care Options, LLC, and the peer/content reviewers for this activity have no relevant conflict of interest to report.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Rajesh Pahwa, MD
Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, Kansas

Rajesh Pahwa, MD, has disclosed that he received:

Consulting fees from Abbott, AbbVie, Acadia, Acorda, Adamas, Cala Health, Global Kinetics, Lundbeck, Neurocrine, Prilenia Therapeutics, PhotoPharmics, Sunovion, Teva Neuroscience, US WorldMeds;
Grant/research support from Abbott, AbbVie, Acorda, Biogen, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec Pharma, Jazz Pharmaceuticals, Kyowa Kirin, Eli Lilly and Company, National Institute of Neurological Disorders and Stroke/National Institutes of Health, National Parkinson Foundation, Parkinson Study Group, Roche, Sunovion, Theranexus, Theravance, US WorldMeds, Voyager.

Stuart Isaacson, MD
Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Stuart Isaacson, MD, has disclosed that he received:

Consulting fees from AbbVie, Acadia, Acorda, Adamas, Addex, Allergan, Amarantus, Auspex, Axovant, Biotie, Britannia, Cynapsus, GE Healthcare, Impax, Ipsen, Kyowa Kirin, Lundbeck, Medtronics, National Parkinson Foundation, Neurocrine, Neuroderm, Orexa, Pfizer, Roche, Sunovion, Teva, UCB, US World Meds, Xenoport, Zambon;
Speaker honoraria from AbbVie, Acadia, Allergan, American Parkinson Disease Association, Britannia, Cynapsus, GE Healthcare, Impax, Ipsen, Lundbeck, Neurocrine, National Parkinson Foundation, Teva, UCB, US World Meds, Xenoport, Zambon; and
Grant/research support from AbbVie, Acadia, Acorda, Adamas, Addex, Allergan, Amarantus, Auspex, Avid, Axovant, AZTherapies, Biogen, Biotie, Cynapsus, Eisai, Eli Lilly and Company, Enterin, GE Healthcare, Impax, Intec Pharma, Ipsen, Kyowa, Lundbeck, Merz, Michael J. Fox Foundation, Neurocrine, Neuroderm, National Institute of Neurological Disorders and Stroke/National Institutes of Health, Orexa, Parkinson Study Group, Pfizer, Pharma2B, Prothena, Roche, Sanofi, Shire, Sunovion, Teva, UCB, US World Meds, Xenoport

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Goal

The goal of this activity is to improve the competence of learners in considering current clinical approaches to address motor fluctuations and OFF time in patients with Parkinson disease.

Accreditation

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The University of Cincinnati designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commerical Support

This activity is supported by educational grants from Acorda Therapeutics, Inc. and Sunovion.

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.      

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above